Approved last May by the Food and Drug Administration, Harrow Health's Vevye drops for the treatment of dry eye syndrome are being hailed as a welcome alternative to current cyclosporine drops.
The revolutionary formulation of Vevye offers reduced inflammation, and increased tear production. Vevye drops have also demonstrated the ability to repair corneal surface damage. Unlike its counterparts, Vevye is the only water-free cyclosporine, which means the drop spreads across the eye allowing the cyclosporine to cover the entire ocular surface. In addition, this water-free solution stays in place for up to 8 hours allowing a continuous delivery of cyclosporine to the surface of the eye.
This systematic delivery of the drug along with the added bonus of it being preservative-free, allows the drops to be dispensed in a convenient multiuse bottle. And while current cyclosporine drops can take up to 3 months to take effect, Vevye has shown to provide consistent effectiveness in just 4 weeks of treatment with continued improvement over an entire year. Vevye drops also are less likely to cause irritation to the eye when dispensed when compared to Restasis and Cequa. As of January 11, 2024, Vevye eye drops are available by prescription only.
For those suffering from dry eye symptoms, VisiVite offers our patented Omega 3 Dry Eye Relief supplement that may be used along with prescription or over-the-counter eye drops. Talk to your doctor before starting a new supplement to make sure there are no contraindications with any current medicines you are taking.
